Abstract | Priapism is defined as a persistent penile erection (typically 4 h or longer) that is unrelated to sexual stimulation. Priapism can be classified as either ischemic or nonischemic. ischemic priapism, the most common subtype, is typically accompanied by pain and is associated with a substantial risk of subsequent erectile dysfunction. Prompt medical attention is indicated in cases of ischemic priapism. The initial management of choice is corporal aspiration with injection of sympathomimetic agents. if medical management fails, a cavernosal shunt procedure is indicated. stuttering (recurrent) ischemic priapism is a challenging and poorly understood condition; new management strategies currently under investigation may improve our ability to care for men with this condition. Nonischemic priapism occurs more rarely than ischemic priapism, and is most often the result of trauma. This subtype of priapism, which is generally not painful, is usually initially managed with conservative treatment.
Introduction
The term 'priapism' is derived from the name Priapus, an ancient Greek god of fertility and protector of horticulture famed for his massive phallus. 1 The first report of priapism in the medical literature was by Petraens, in 1616. 2 Priapism is defined as a penile erection that persists for 4 h or longer and that is unrelated to sexual stimulation. 3 The condition, which can affect males of any age, occurs in a nonischemic variant (which is almost universally associated with trauma, is typically not painful, and is not typically a medical emergency) and a much more common ischemic variant (which is typically painful and requires urgent clinical management). Stuttering (or recurrent) priapism is a variant of ischemic priapism that is distinguished by its recurrent nature.
The principal goal in the management of patients with ischemic priapism is prompt restoration of cavernosal blood flow to prevent end-organ damage and subsequent erectile dysfunction. A variety of medical and surgical techniques have been developed to facilitate this clinical objective. Management of nonischemic priapism may be tailored to patient preference. This Review will focus on current therapies, new treatments and our own experience in the management of priapism.
Ischemic priapism
Ischemic priapism (formerly known as 'low-flow' or 'veno-occlusive' priapism) is defined as a prolonged, painful penile erection that prevents freshly oxygenated blood from entering the corpora cavernosa, leading to tissue ischemia. Ischemic priapism typically affects the paired corpora cavernosa but not the corpus spongiosum or glans penis; consequently, the glans penis is typically not engorged in ischemic priapism.
Ischemic priapism is a compartment syndrome of the penis which carries a high risk of end-organ damage and erectile dysfunction. The condition arises as a result of obstruction of blood flow out of the penis through penile veins and/or failure of the smooth muscle within the spongy erectile tissue of the penis to contract normally.
Epidemiology
An overall incidence of 1.5 cases of ischemic priapism per 100,000 person-years was reported in the general population of the Netherlands between 1995 and 1999. 4 The incidence was higher (2.9 cases per 100,000 personyears) in men aged 40 years or above, 4 possibly as a result of increased utilization of intra cavernosal pharmacotherapy for erectile dysfunction in this population. 5 Indeed, when the use of intra cavernosal pharmacotherapy was excluded as a cause of ischemic priapism, the incidence decreased to 0.9 cases per 100,000 personyears. 4 Another major risk factor for ischemic priapism is sickle-cell disease; the lifetime probability of a man with sickle-cell disease developing priapism is between 29% and 42%. [6] [7] [8] Unfortunately, awareness of priapism seems to be relatively low in men with sickle-cell disease.
Delay in presentation to a health care provider is a consequence of public misunderstanding of the potential gravity of a prolonged penile erection, and might have serious repercussions with respect to long-term maintenance of erectile capacity. Prolonged corporal ischemia reviews and acidosis can lead to trabecular interstitial edema, cellular death, corporeal fibrosis, erectile dysfunction and, in extreme cases, penile necrosis. 6, 9 Because of the potentially serious repercussions of ischemic priapism, increased patient education and public awareness of this condition are warranted.
Pathophysiology and etiology
Reported etiologies for ischemic priapism are varied, and are summarized in Box 1. Although some of these risk factors are well established, others have been reported only in single cases. It is estimated that around half of ischemic priapism cases are idiopathic. 9 Hematologic hyperviscosity For many years, trapping of deformed, hyperviscous red blood cells in the erectile bodies and the veins that drain them was thought to be the leading cause of ischemic priapism. Although this proposed mechanism has come under close scrutiny in past years, the increased risk of ischemic priapism in patients with blood dyscrasias (such as sickle-cell disease, thalassemia, leukemia, presence of the hemoglobin olmsted variant, thrombo philia, and multiple myeloma) is undisputed. [10] [11] [12] [13] Sickle-cell disease is the leading hematologic cause of ischemic pri pism, accounting for approximately 23% of adult cases and 63% of pediatric cases.
14 An increase in blood viscosity is often associated with the use of some forms of high-fat parenteral hyperalimentation and hemo dialysis, and can occur as a result of glucose-6-phosphate dehydro genase deficiency; it is through this increased viscosity that these treatments and this condition are thought, on rare occasions, to precipitate ischemic priapism. [15] [16] [17] Nonhematologic malignant neoplasms Men with advanced cancer of the pelvic organs may develop priapism owing to tumor infiltration of the veins that drain the penis. Cancers of the penis, urethra, bladder, prostate, kidney and rectum have been linked to priapism.
18-23

Drugs
The smooth musculature of the cavernosal arteries and corpora cavernosa is designed to relax and dilate during sexual stimulation to permit enhanced blood flow to the penis. with engorgement, veins that drain the penis are compressed and blood becomes trapped in the corpora cavernosa. when sexual arousal has subsided, the cavernosal smooth muscle contracts, leading to the opening of venous outflow channels and the restoration of blood flow from the penis. A number of drugs, both prescription and recreational, can impair the ability of cavernosal smooth muscles to contract, potentially leading to ischemic priapism (see Box 1). Conservative management might be adequate for nonischemic priapism ■ herniation or stenosis, cauda equine syndrome, the use of local or general anesthesia, and neurologic infections, such as syphilis, have been linked to priapism. [24] [25] [26] [27] [28] [29] [30] The leading hypothesis for the mechanism by which neuro logic lesions mediate ischemic priapism is neural dys regulation-that is to say, disruption of autonomic nervous system mechanisms that mediate penile vascular muscle tone. 31 
Neurologic conditions
Nonischemic priapism
Also known as 'high-flow' or 'arterial' priapism, this rare condition occurs when there is unregulated arterial flow of blood into the corpora cavernosa owing to rupture of a branch of the cavernosal artery. This rupture is almost always the result of penile, perineal or pelvic trauma; it has also been associated with iatrogenic trauma.
In nonischemic priapism, the penis is enlarged and firm compared to its baseline flaccid state, but it is usually not as rigid as it would be with normal sexual arousal. This subtype of priapism is typically not painful; consequently, patients tend to seek medical attention much later than those with ischemic priapism (initial presentation upwards of 3 years after onset of the condition has been reported). 32 Epidemiology and pathophysiology To our knowledge, nonischemic priapism was first reported in the medical literature in 1960. 33, 34 There are few data on the epidemiology of this disorder, but it is much rarer than ischemic priapism.
Nonischemic priapism occurs secondary to unregulated blood flow from an arterial source into the corpora cavernosa. It differs from ischemic priapism because the increased inflow does not lead to complete engorgement and obstruction of the venous outflow channels; consequently, pain and ischemia do not develop. The most common cause of this condition is thought to be injury to a penile artery, with subsequent delayed formation of a fistula into the corpus cavernosum. 35, 36 In our view, arterial weakening associated with trauma might not induce fistula formation immediately, but subsequent penile erection (sexual or nocturnal) might reviews increase the pressure in the cavernosal artery so that rupture occurs.
Although traumatic injury is by far the most common etiology for nonischemic priapism, this condition has been reported to arise as a complication of medical and surgical management of ischemic priapism. [37] [38] [39] other surgical procedures associated with the occurrence of nonischemic priapism include cold-knife internal urethrotomy for urethral stenosis, 40 hydraulically induced erection during Nesbit corporoplasty, 41 deep dorsal vein arterialization for vasculogenic impotence, 42 and selfadministration of intracavernosal pharmacotherapy for erectile dysfunction. 43 Testosterone supplementation in boys, 44 sickle-cell disease, 45, 46 acute lymphoblastic leukemia, 47 Fabry's disease (a condition of abnormal lipid deposition in blood vessels), 48 tumor metastases to the corpora cavernosa, 49 and para neoplastic syndromes 25 have been reported as nonsurgical causes of nonischemic priapism. Theoretically, non ischemic priapism associated with dyscrasia might be a variant of ischemic priapism in which venous outflow is not completely compromised. Nonischemic priapism associ ated with Fabry's disease is thought to occur secondary to endothelial or autonomic ganglia dysfunction, or both. Metastatic deposits might alter the flow of blood in the corpora cavernosa such that a fistulous connection develops.
Evaluation of prolonged penile erection
evaluation of a patient with a prolonged penile erection involves four components: patient history, physical examination, laboratory testing and imaging studies. After diagnosis, a strategy for management of the condi tion can be followed (see below, and Figure 1 ).
Patient history and physical examination
The first and most important step on presentation is to determine whether the priapism is ischemic or non ischemic. Ischemic priapism is suspected if the patient has penile pain, has used a drug that is known to be associ ated with ischemic priapism, has sickle-cell disease or another blood abnormality, or if the physical examina tion reveals a fully rigid penile shaft. 3 If there is no or minimal pain, a history of trauma or surgery, and the physical examination shows that the penis is merely engorged or partially erect, nonischemic priapism is suspected. 3 
Laboratory tests
A complete blood count and sickle cell 'prep' should be obtained to exclude abnormalities in red or white blood cells or platelets. Urine toxicology tests might be requested if the use of illicit drugs is suspected. A corporal blood specimen might be aspirated to assess oxygen tension and acidity in the corpora cavernosa. Blood aspirated from a patient with ischemic priapism has been described as 'crankcase oil-like' owing to its deoxygenated state and viscosity, whereas specimens from patients with nonischemic priapism typically resemble normal arterial blood.
3 Table 1 summarizes the typical values of gases found in the blood from patients with priapism. It is important to bear in mind, however, that all cases of priapism begin with an influx of arterial blood and, as such, analysis of cavernosal blood gases, if done early, might be misleading.
Imaging studies
Color duplex ultrasonography of the penis and perineum is the imaging test of choice to assess blood flow throughout the length of the corpora cavernosa. Patients with ischemic priapism have no blood flow in the cavernosal arteries, whereas those with nonischemic priapism have normal-to-high blood flow; in some cases, the arterial fistulae or pseudoaneurysms causing the increased penile blood flow might also be noted (Figure 2 ). The use of magnetic resonance angiography, 50 contrast-enhanced CT, 51 and nuclear medicine scans 52 for the evaluation of priapism has been reported, but these tests should not be considered the standard of care. Arteriography can be used to precisely localize arterial fistulae in non ischemic priapism; typically this approach is only undertaken in the context of attempted superselective embolization of the affected vessel. 53 
Treatment of ischemic priapism
Ischemic priapism is a medical emergency, and a better outcome can be expected with prompt treatment. Restoration of blood flow into the corpora cavernosa and prevention of end-organ damage are the primary goals Prompt therapy, if available, is recommended for the underlying cause of ischemic priapism. For priapism associated with sickle-cell disease, intravenous fluids, analgesics, and supplemental oxygen have been the traditional treatments of choice. exchange blood transfusion has been used to treat priapism associated with sickle-cell disease, although there is some doubt regarding the efficacy of this treatment. 54 In the case of priapism caused by advanced pelvic cancer, treatment with radiation therapy or chemotherapy might be helpful for reducing the size of bulky tumors. 18 However, treatment of underlying conditions should not delay treatment that is intended specifically to reverse penile erection.
Medical treatments
The use of oral sympathomimetic treatments, such as terbutaline or pseudoephedrine, has been reported to be superior to placebo therapy in the management of ischemic priapism induced by intracavernosal pharmaco therapy, but this treatment has a low clinical efficacy (28-36%) 55 and so should not be viewed as the standard of care; it might, however, be considered as an adjunctive treatment prior to more advanced urologic intervention.
Corporal aspiration is a simple intervention that often produces softening of the erect penis and relief of pain, with a success rate of around 30%.
3 During aspiration, a butterfly needle (19 or 21 gauge) is inserted into either the head or shaft of the penis and blood is aspirated. Typically, a 'penile block' of local anesthetic is administered before this treatment to minimize patient discomfort. while corporal aspiration is an important intervention, in most cases this procedure is insufficient by itself to completely reverse the process of ischemic priapism. 56 Intracavernosal injection of sympathomimetic drugs (such as ephedrine, epinephrine, norepinephrine, metaraminol and phenylephrine) is the standard of care in the treatment of ischemic priapism. 57 Phenylephrine, a selective α1-adrenergic receptor agonist without β-mediated inotropic and chronotropic cardiac effects, is the sympathomimetic agent of choice due to its safety profile. 3, 58 The medication is typically administered at a concentration of 0.1-0.5 mg/ml of sterile saline, although this concentration can be adjusted depending on the potential hemodynamic response of the patient to sympatho mimetic treatment. Repeat injections can be given at 3-5 min intervals until the penis notably detumesces.
Close monitoring for dizziness, headache, acute hypertension, reflex bradycardia, tachycardia, palpitation and cardiac arrhythmia is recommended for patients undergoing sympathomimetic treatment for ischemic priapism. Serial or continuous measurement of blood pressure and heart rate should be considered for all patients, particularly those with high blood pressure or heart disease. 53, 56 Imaging studies are not routinely necessary in the management of ischemic priapism, but they might be utilized in some equivocal cases or to gauge clinical response to treatment.
The success rate of intracavernosal injection of sympatho mimetic drugs, with or without aspiration, is between 43% and 81%. 3 one study describes almost 100% success if the procedure is carried out within 12 h of the onset of priapism. 59 Decreased efficacy of the treatment in ischemic priapism of long duration is probably the result of an impaired response of the smooth muscle reviews to the sympathomimetic drugs after extended periods of hypoxia and acidosis. 60 
Surgical treatments
Surgical intervention for ischemic priapism is indicated when repeated sympathomimetic injections have failed to yield results within 1 h of treatment. Surgery for ischemic priapism consists exclusively of shunt procedures to alleviate corporal compartment syndrome and penile pain. Although all shunt procedures carry the risk of erectile dysfunction, it is unclear what proportion of the erectile dysfunction cases that arise after ischemic priapism managed by shunting is secondary to the disease process and how much is attributable to the procedure itself. other general risks associated with all types of shunt carried out for priapism include failure to reverse the condition, pain, bleeding and infection. very rare complications include abscess formation, urethro cutaneous fistula and pulmonary embolism. 3 
Distal shunts
The cavernoglanular shunt is usually carried out as a first line of surgical treatment for refractory ischemic priapism. This procedure creates a connection between one or both of the corpora cavernosa and the glans penis. The shunt can be created by passing a large biopsy needle or #11-blade scalpel through the glans into the corpora cavernosa (the winter shunt and ebbehoj shunt, respectively), or via transglanular anastomosis from the corpora cavernosa to the glanular spongiosum (the Al-Ghorab shunt). Success rates for distal shunts range from 66% to 74%, with a 25% incidence of erectile dysfunction after treatment. 3 Proximal shunts A proximal cavernospongiosal shunt can be created by a perineal incision, through which the proximal portion of the corpora cavernosa are anastomosed to the proximal corpus spongiosum (known as the Quackels procedure). This approach has a reported success rate of 77%, with an ensuing 50% incidence of erectile dysfunction. 3 
Venous shunts
Cavernosaphenous shunts are made between the corpora cavernosa and the saphenous vein (known as the Grayhack procedure) or the superficial or deep dorsal vein of the penis (the Barry procedure). Reported rates of success using these procedures are around 76%; approximately 50% of patients subsequently experience erectile dysfunction. 3 Novel procedures Kilinc 61 has described a new temporary artificial cavernosal-cephalic shunt in 15 patients who presented with ischemic priapism with a mean duration of 20 h. For this procedure, two 18-gauge angiocaths were placed into the corpora cavernosa (one in each) via a transglanular approach. one angiocath was infused with a heparinized sterile saline solution and the other was connected to a third 18-gauge angiocath placed in the cephalic vein of the arm. By this means, a continuous corporalto-systemic circulation shunt was created. Irrigation was maintained for 30 min, but resumed if detumescence had not occurred; this approach was repeated as needed until the penis became flaccid or for a total of 6 h. The complete detumescence rate was 87% (13 out of the 15 patients), with a mean treatment duration of 110 min (durations ranged from 30 to 300 min); the two patients that did not respond were successfully managed using the Grayhack shunt. of the 13 successfully treated patients, 8 manifested signs of erectile dysfunction. 61 The results of this approach are encouraging, although there are concerns about the potential for microemboli or other complica tions that might arise from extracorporal shunting. It could also be argued that the procedure is not a true shunt, but rather a semi-automated means of corporal irrigation.
At our institution, we favor the T-shunt for ischemic priapism that is refractory to treatment with intracavernosal injection of a selective α1-adrenergic receptor agonist. This shunt is created by passing a #10-blade scalpel through the head of the penis into the ipsilateral corpus cavernosum after a local anesthetic is administered. The blade is inserted until the hub contacts the glans penis, and is then rotated 90° to ensure the creation of a large fistula (Figure 3) , before being removed and expressing venous blood from the penis. If it is not Figure 2 | Color duplex ultrasound image of nonischemic priapism following a straddle injury. A ruptured branch of the cavernosal artery pumping blood to a cystic cavity within the corpus cavernosum is shown. Note the jet of arterial blood (yellow). reviews possible to 'indent' the corpora cavernosa using gentle pressure 10-15 min after the procedure, the process can be repeated on the contralateral side (the TT-shunt). If the corpora cavernosa remain rigid even after TT-shunt (as might occur in situations in which priapism has lasted over 3 days), corporal 'tunneling' might be performed by passage of a 20-24 F urethral sound or dilator through the glanular incisions and into the ipsilateral corpus spongiosum to restore proximal-distal circulation (the TTT-shunt; Figure 4) . A TTT-shunt might be required in cases of prolonged ischemic priapism in which tissue edema prevents proximal-distal circulation. 62 we have performed this procedure in 13 men with excellent results with respect to resolution of priapism and relief of pain. 63 The theoretical advantage of this approach is that the shunt can be enlarged so as to include both distal and proximal portions of the corpora cavernosa, thereby facilitating improved drainage of the entire cavernosal body ( Figure 5 ).
Burnett and Pierorazio 64 describe a T-shunt-like procedure in which a dilator is passed into the corporus cavernosum through an Al-Ghorab-type glanular incision. This technique was utilized successfully (with relief of priapism) in three patients who presented with priapism of 2, 5 and 6 days duration. one patient reported the return of erectile function 1 month after the procedure was carried out, but was subsequently lost to follow-up. The other two patients had not resumed intercourse by the 3-month or 5-month follow-up visits.
Postoperative care
Pressure should be exerted intermittently on the body of the penis to promote fistula patency. Tight compressive dressings should be avoided as they might compromise drainage. even after a successful shunt, the penis might appear partially erect owing to persistent edema. In case of doubt, duplex ultrasonography should be used to assess blood flow. Repeat sampling of blood from the corpora cavernosa to assess the oxygen content within the penis can be used to assess the response to treatment, although changes in oxygen tension and pH values might not occur immediately after treatment. Intracavernosal pressure measurement can also be used to assess the response to shunt treatment. A value less than 40 mmHg indicates a successful procedure; if the pressure exceeds 40 mmHg, additional treatment might be needed. 65 Some authors advocate the immediate placement of penile prostheses in patients with ischemic priapism of long duration, owing to the difficulty in placing such prostheses after corporal fibrosis has occurred. 66, 67 This option should be discussed with patients, but should not 
Management of stuttering priapism
Patients with stuttering priapism who are deemed reliable enough may be instructed how to perform intracavernosal injection of sympathomimetic drugs on themselves, and provided with the appropriate medication. This management may permit 'at home' treatment of stuttering priapism. 56 Antiandrogens or analogs of gonadotropin-releasing hormone have been used to prevent nocturnal penile tumescence in men with stuttering priapism. This treatment has been effective in some cases, with preservation of erectile function, but there are significant risks associated with prolonged hypogonadism. 68, 69 Androgen ablation is not considered a safe therapy for ischemic pria pism in prepubertal or pubertal boys, as this approach might seriously affect sexual development. other medical therapies, such as hydroxyurea, gabapentin, methylene blue, oral baclofen, digoxin, etilephrine, procyclidine and estradiol, have been reported to prevent stuttering priapism, but the evidence for their clinical use is not robust.
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Treatment of nonischemic priapism
Typically, nonischemic priapism does not cause significant end-organ damage and can be managed conservatively. Rest, time, and the use of ice packs have been shown to resolve the condition in some patients. 78 Some men choose to defer therapy, and reportedly tolerate nonischemic priapism while maintaining adequate erectile function over long periods of time. 52, 79 others, however, opt for treatment that produces a more immediate effect. 80 Treatment of nonischemic priapism is geared towards elimination of the cavernosal artery fistula. 81 Embolization Angiography with superselective embolization is the treatment of choice if prompt, definitive management of nonischemic priapism is desired. The first report of success ful selective arterial embolization for nonischemic priapism was by wear and co workers. 53 embolization has been performed using gel foam, coils, autologous blood clot, polyvinyl alcohol and N-butylcyanoacrylate. [82] [83] [84] [85] Microcoils are easy to place and do not dissolve, thereby avoiding the risk of recurrent nonischemic priapism; however, these permanent embolic devices might elicit a greater risk of erectile dysfunction than gel foam or autologous blood clots. Autologous blood clots are cheap, show low anti genicity, are unlikely to induce a foreign-body reaction, and are temporary, allowing recanalization of the caver nosal artery and restoration of penile blood flow in the fistula segment after healing. 86 Success rates of 100% with complete preservation of erectile function have been reported following treatment with superselective emboliza tion using an autologous blood clot, although second embolization sessions might be required. 87, 88 It has been suggested that immediate repeat embolization might not be required in all cases, as cavernosal-spongiosal communications, which might supply the fistula after embolization, might spontaneously close. 89 The penile arteries of young children are narrower than those of adults, so superselective embolization might be more disruptive and should be undertaken with extreme caution in young patients. 90 ,91 embolization also carries risks of exposure to radiation and contrast medium. Color duplex ultrasonography can be used as an alternative to intravenous contrast medium for direction of the angiographic catheter within the penile arteries; while this approach minimizes contrast exposure, it is technically much more challenging. 92, 93 overall initial success rates for embolization are 73-89%, although repeat procedures might be required. A 20-25% incidence of erectile dysfunction has been reported. 80, [94] [95] [96] The rate of permanent erectile dysfunction is likely to vary according to the type of embolus used. Reported complications of pudendal artery emboliza tion are rare, but include penile gangrene, gluteal ischemia, purulent cavernositis, perineal abscess, and migration of embolization material. 
Alternative treatments
Alternative treatments for patients with nonischemic pria pism who decline superselective embolization include intracavernosal injection of methylene blue, 98 temporary blockage and thrombus formation using an ultrasonography probe to compress the arteriosinusoidal fistula and promote clotting, 99, 100 or injection of thrombin under ultrasound guidance. 101 ligation of the cavernosal artery is another option that is available in cases where embolization fails. It can be performed in two ways: either by ligating the cavernosal artery at the outlet from Alcock's canal, or by performing an exploratory corporotomy followed by ligation of the arterial fistula. 102 ligation of the cavernosal artery carries a substantial risk of worsening erectile function. Selective ligation of the fistula decreases the risk of erectile dysfunction, but the presence of a pseudocapsule of tissue around the fistula must be documented prior to surgery using duplex ultrasonography. A pseudocapsule is essential, as it is impossible to ligate the fistula without this tissue rind. Typically, it takes 6 months for a capsule to form, so fistula ligation should not be contemplated until 6 months after presentation.
we have successfully used antiandrogen therapy for nonischemic priapism in four patients, with positive results (T. F. lue, unpublished data).
New directions for priapism treatment
Daily treatment with low-dose inhibitors of the enzyme phosphodiesterase type 5 (PDe5) is a novel and investigational means of treating stuttering priapism. Mice that lack endothelial nitric oxide synthase have lower levels of PDe5 compared to controls, and manifest priapism-like activity in penile hemodynamic studies. PDe5 is responsible for breaking down cyclic GMP, an intracellular messenger that promotes vasodilation and penile erection. lower levels of PDe5 might cause prolonged presence of cyclic GMP and, consequently, erections of greater duration. 103 Inhibitors of PDe5 have been shown to upregulate the expression of PDe5 in myocytes in vitro, 104 a result that, if translated to an in vivo situation in cavernosal smooth muscle, might antagonize priapism.
A pilot study by Burnett et al. 105 reported that chronic administration of a PDe5 inhibitor to seven patients with stuttering priapism resulted in marked clinical improvements in six of these patients while maintaining their capacity for sexual erections. Although inhibition of PDe5 might represent an exciting new means of therapy for priapism, further studies are needed before this treatment should be considered outside of a research setting.
Conclusions
Ischemic priapism is a urologic emergency, requiring prompt recognition and treatment to avoid long-term complications, such as erectile dysfunction. Nonischemic priapism may be managed conservatively, although treatment options are available for men who desire or require a more prompt resolution of the problem. A number of reliable treatments are available for both ischemic and nonischemic priapism. Stuttering priapism is still not well understood, and there is currently no standardized treatment for this condition. Future work will hopefully help to uncover the molecular mechanisms of ischemic priapism and improve our ability to care for patients with this condition.
